* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *
Full Coverage

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

yahoo.com
May 22, 2008
        
Story Timeline:  143 days

LOS ANGELES----Cougar Biotechnology, Inc. today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology , which will take place May 30th through June... [read full story]                    

Add Comment
Latest article on this story:

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

 drugs.com May 22, 2008
First article on this story:

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

 finanznachrichten.de May 22, 2008
Selected publications with coverage of this story:
redorbit.com yahoo.com drugs.com finanznachrichten.de
RELATED
Found 3 documents:

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

drugs.com
May 22, 2008
        

LOS ANGELES--(BUSINESS WIRE)--May 22, 2008 - Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during...

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

redorbit.com
May 22, 2008
        

Posted on: Thursday, 22 May 2008, 09:01 CDT Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of...

Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society...

finanznachrichten.de
May 22, 2008
        

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take...

Related categories

ASCO